RALEIGH, N.C. – August 27, 2026
Slate Medicines Inc. announced that the first participant has been dosed in its Phase 1 clinical study of SLTE-1009, an investigational subcutaneous monoclonal antibody being developed for the prevention of migraine. The milestone advances Slate’s lead clinical program into human testing as the company evaluates the candidate’s pharmacokinetics and safety in healthy volunteers. The Phase 1 study is being conducted in Australia and is designed to assess both single- and multiple-ascending doses of SLTE-1009.
Slate Medicines Advances SLTE-1009 into Phase 1
The Phase 1 single- and multiple-ascending dose study will evaluate the safety and pharmacokinetic profile of SLTE-1009 in healthy participants. The study represents an important development milestone for Slate as it works to establish the candidate’s initial clinical profile before advancing into later-stage migraine prevention studies. Topline safety and pharmacokinetic data are expected in mid-2027. The company is particularly evaluating whether the candidate’s pharmacokinetic characteristics can support an infrequent subcutaneous dosing approach, which could potentially reduce treatment burden for patients requiring long-term migraine prevention.
Dual PACAP and VIP Targeting Differentiates Candidate
Immuneering previously reported results from an open-label, single-arm Phase 2a study involving 55 patients with first-line metastatic pancreatic cancer who received atebimetinib 320 mg once daily plus modified gemcitabine/nab-paclitaxel (mGnP). At the April 24, 2026 data cutoff, the study reported a median overall survival of 17.3 months, with a median follow-up of 11.6 months. The company also reported that 84% of evaluable patients maintained or gained weight at three months, an important measure in a disease frequently associated with substantial weight and muscle loss. Among treatment-related adverse events of Grade 3 or higher occurring in at least 10% of patients, anemia occurred in 16% and neutropenia in 18%, with both identified as chemotherapy-related.
Advertisement
Atebimetinib Strategy Moves Toward Phase 3 Evaluation
The initiation of clinical dosing gives Slate an opportunity to evaluate whether the preclinical characteristics of SLTE-1009 translate into a suitable human safety and pharmacokinetic profile. Migraine remains a significant therapeutic area in which patients may require preventive treatments over extended periods, while currently available approaches include established CGRP-targeted therapies. Slate is positioning SLTE-1009 as a differentiated preventative approach based on simultaneous PACAP and VIP blockade and potentially infrequent dosing. The upcoming Phase 1 results will be important in determining the candidate’s dose levels, exposure characteristics and tolerability and will help inform the next stages of its clinical development program.
Source:Slate Medicines, press relese
